A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Neuromyelitis optica
  • Focus Therapeutic Use
  • Acronyms RIN-1
  • Sponsors Zenyaku Kogyo
  • Most Recent Events

    • 17 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
    • 30 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top